BR112014012985A2 - métodos de conservação de composições farmacêuticas injetáveis compreendendo uma ciclodextrina e uma droga hidrofóbica - Google Patents

métodos de conservação de composições farmacêuticas injetáveis compreendendo uma ciclodextrina e uma droga hidrofóbica

Info

Publication number
BR112014012985A2
BR112014012985A2 BR112014012985A BR112014012985A BR112014012985A2 BR 112014012985 A2 BR112014012985 A2 BR 112014012985A2 BR 112014012985 A BR112014012985 A BR 112014012985A BR 112014012985 A BR112014012985 A BR 112014012985A BR 112014012985 A2 BR112014012985 A2 BR 112014012985A2
Authority
BR
Brazil
Prior art keywords
cyclodextrin
methods
pharmaceutical compositions
hydrophobic drug
injectable pharmaceutical
Prior art date
Application number
BR112014012985A
Other languages
English (en)
Other versions
BR112014012985B1 (pt
Inventor
Aileen Willis Amanda
Lau Kai
Shawn Pasloske Kirby
Jane Richardson Sarah
Original Assignee
Jurox Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011904970A external-priority patent/AU2011904970A0/en
Application filed by Jurox Pty Ltd filed Critical Jurox Pty Ltd
Publication of BR112014012985A2 publication Critical patent/BR112014012985A2/pt
Publication of BR112014012985B1 publication Critical patent/BR112014012985B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Materials Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo métodos de conservação de composições farmacêuticas injetáveis compreendendo uma ciclodextrina e uma droga hidrofóbica a invenção está relacionada a composições farmacêuticas injetáveis, métodos de uso e formulação, onde as composições compreendem: um ou mais complexos hidrossolúveis, com cada complexo compreendendo uma ciclodextrina ou seu derivado e uma droga hidrofóbica; no mínimo um conservante; e no mínimo um cossolvente. as composições são efetivamente conservadas de acordo com a farmacopeia europeia 2011, test for efficacy of antimicrobial preservation, satisfazendo no mínimo o critério b para medicamentos parenterais, e com a farmacopeia americana 2011, guidelines for antimicrobial effectiveness testing, satisfazendo o critério para produtos de categoria 1 (injetáveis).
BR112014012985-1A 2011-11-29 2012-11-27 Composição farmacêutica injetável, seu método de produção e uso, bem como método de conservação de uma composição farmacêutica injetável e uso de pelo menos um co-solvente e pelo menos um conservante BR112014012985B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2011904970 2011-11-29
AU2011904970A AU2011904970A0 (en) 2011-11-29 Pharmaceutical compositions
AU2012904962A AU2012904962A0 (en) 2012-11-09 Pharmaceutical compositions
AU2012904962 2012-11-09
PCT/AU2012/001452 WO2013078500A1 (en) 2011-11-29 2012-11-27 Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug

Publications (2)

Publication Number Publication Date
BR112014012985A2 true BR112014012985A2 (pt) 2017-06-13
BR112014012985B1 BR112014012985B1 (pt) 2020-05-12

Family

ID=48534526

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014012985-1A BR112014012985B1 (pt) 2011-11-29 2012-11-27 Composição farmacêutica injetável, seu método de produção e uso, bem como método de conservação de uma composição farmacêutica injetável e uso de pelo menos um co-solvente e pelo menos um conservante

Country Status (19)

Country Link
US (4) US9492552B2 (pt)
EP (2) EP3446692A1 (pt)
JP (2) JP5819005B2 (pt)
KR (1) KR101922752B1 (pt)
CN (2) CN103998046B (pt)
AR (1) AR089004A1 (pt)
AU (1) AU2012268889B2 (pt)
BR (1) BR112014012985B1 (pt)
CA (1) CA2852716C (pt)
DK (1) DK2785352T3 (pt)
ES (1) ES2784629T3 (pt)
HK (1) HK1198325A1 (pt)
HR (1) HRP20200567T1 (pt)
IL (1) IL232860B (pt)
IN (1) IN2014KN01341A (pt)
SG (2) SG10201506273PA (pt)
TW (1) TWI552770B (pt)
WO (1) WO2013078500A1 (pt)
ZA (1) ZA201402895B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
PT2806877T (pt) 2012-01-23 2019-12-06 Sage Therapeutics Inc Formulações de esteroides neuroativos que compreendem um complexo de alopregnanolona e beta-ciclodextrinas de éter sulfobutílico
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
ES2653765T3 (es) 2012-12-21 2018-02-08 Sanofi Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
JP6180241B2 (ja) * 2013-08-29 2017-08-16 学校法人同志社 シクロデキストリン誘導体及び医薬組成物
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016160310A1 (en) * 2015-04-01 2016-10-06 The Chemours Company Fc, Llc Stabilized composition for combined odor control and enhanced dewatering
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
KR101718733B1 (ko) * 2015-08-21 2017-03-22 국제약품 주식회사 레바미피드의 가용화 방법 및 이에 의해 제조된 안구건조증 치료용 액제
NL2015865B1 (en) * 2015-11-27 2017-06-13 Le Vet B V Maropitant Formulation.
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
CN110215430A (zh) * 2018-03-02 2019-09-10 刘力 新型可注射的硝酸甘油药物组合物
KR102141826B1 (ko) * 2018-10-05 2020-08-07 건국대학교 산학협력단 양이온성 베타 시클로덱스트린 올리고머를 이용한 외부 pH 자극 반응형 자가치유성 하이드로젤
US20220000797A1 (en) * 2018-11-07 2022-01-06 (Bika Biotechnology (Guangzhou) Co., Ltd) Clear propofol injection and preparation method therefor
WO2020167476A1 (en) 2019-02-15 2020-08-20 Saol International Limited Injectable phenol formulations and methods of their use
EP3725298A1 (en) 2019-04-16 2020-10-21 Faes Farma, S.A. Stable and preserved pharmaceutical compositions of bilastine
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
EP3766475A1 (en) 2019-07-15 2021-01-20 OP-Hygiene IP GmbH Wipes
FR3117337B1 (fr) * 2020-12-10 2023-04-28 Centre Hospitalier Univ De Lille Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable
KR20230122271A (ko) 2022-02-14 2023-08-22 주식회사 에이아이인사이트 파라벤계 보존제의 안정성 증진용 조성물 및 이를 포함하는 보존제

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728509A (en) 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
TW401300B (en) 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
JPH06293638A (ja) 1993-04-06 1994-10-21 Lion Corp 安定なビタミンａ類点眼剤
ZA962214B (en) * 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
JP3934705B2 (ja) 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
TW434023B (en) 1995-09-18 2001-05-16 Novartis Ag Preserved ophthalmic composition
EP1109581A1 (en) 1998-09-02 2001-06-27 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
AUPQ633900A0 (en) 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
IN187686B (pt) * 2000-06-21 2002-06-08 Bharat Serums & Vaccines Ltd
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
JP2003089632A (ja) 2001-09-17 2003-03-28 Otsuka Pharmaceut Factory Inc 注射用水性製剤
JP2005522422A (ja) * 2002-02-01 2005-07-28 シモダ、バイオテック（プロプライエタリー）リミテッド 医薬組成物
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
JP4275394B2 (ja) 2002-12-05 2009-06-10 株式会社大塚製薬工場 注射用シロスタゾール水性製剤
PT1713504T (pt) 2004-01-30 2017-08-29 Zoetis Services Llc Conservantes antimicrobianos para obter uma formulação multidose utilizando beta-ciclodextrinas para formas galénicas líquidas
US6969706B1 (en) 2004-05-12 2005-11-29 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
JP5577021B2 (ja) 2005-02-17 2014-08-20 アボット・ラボラトリーズ 動物における障害を治療および予防するための薬剤組成物の経粘膜投与
EP1951258A4 (en) 2005-11-18 2013-01-02 Astrazeneca Ab LIQUID FORMULATIONS
PE20120029A1 (es) * 2008-11-15 2012-02-13 Rib X Pharmaceuticals Inc Composiciones antimicrobianas
GB2491491B (en) * 2010-01-21 2014-07-30 Drawbridge Pharmaceuticals Pty Ltd Anaesthetic formulation

Also Published As

Publication number Publication date
EP2785352A1 (en) 2014-10-08
ZA201402895B (en) 2015-11-25
US10188664B2 (en) 2019-01-29
JP6095707B2 (ja) 2017-03-15
US20170014428A1 (en) 2017-01-19
CN103998046B (zh) 2021-04-06
HK1198325A1 (zh) 2015-04-02
HRP20200567T1 (hr) 2020-06-26
TWI552770B (zh) 2016-10-11
IN2014KN01341A (pt) 2015-10-16
JP2014533703A (ja) 2014-12-15
JP5819005B2 (ja) 2015-11-18
US20190125762A1 (en) 2019-05-02
TW201328721A (zh) 2013-07-16
DK2785352T3 (da) 2020-05-25
SG10201506273PA (en) 2015-09-29
ES2784629T3 (es) 2020-09-29
WO2013078500A1 (en) 2013-06-06
ES2784629T8 (es) 2020-11-23
CA2852716A1 (en) 2013-06-06
BR112014012985B1 (pt) 2020-05-12
US20230293550A1 (en) 2023-09-21
US20140336163A1 (en) 2014-11-13
CN107261152A (zh) 2017-10-20
CA2852716C (en) 2015-11-17
AR089004A1 (es) 2014-07-23
KR20140113629A (ko) 2014-09-24
EP3446692A1 (en) 2019-02-27
AU2012268889A1 (en) 2013-06-13
CN103998046A (zh) 2014-08-20
IL232860B (en) 2019-10-31
IL232860A0 (en) 2014-07-31
EP2785352B1 (en) 2020-03-11
NZ706101A (en) 2016-03-31
JP2015145364A (ja) 2015-08-13
EP2785352A4 (en) 2015-07-29
KR101922752B1 (ko) 2018-11-27
AU2012268889B2 (en) 2013-12-19
CN107261152B (zh) 2022-03-04
SG11201401597TA (en) 2014-05-29
US9492552B2 (en) 2016-11-15
NZ624592A (en) 2015-07-31

Similar Documents

Publication Publication Date Title
BR112014012985A2 (pt) métodos de conservação de composições farmacêuticas injetáveis compreendendo uma ciclodextrina e uma droga hidrofóbica
BR112017026287A2 (pt) composições de hidroxipropil beta-ciclodextrina e métodos
UY35907A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmaceuticas que las contienen, así como su uso para la preparación de medicamentos
BR112016009669A8 (pt) produtos farmacêuticos, método para tratar câncer e uso de um composto
BR112014031279A2 (pt) composições sinérgicas para a proteção de culturas agrícolas e o uso das mesmas
CL2009000902A1 (es) Composicion que comprende posaconazol disuelto o disperso molecularmente en un polimero derivado de hidroxipropilcelulosa; formulacion farmaceutica que comprende a la composion; un proceso para preparar a la composicion mediante fusioextrusion; y su uso para tratar una infeccion micotica.
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
BR112014031060A2 (pt) composto de fórmula 1a; composição farmacêutica; uso do composto; método para tratamento de infecção fúngica em um paciente; produto de proteção de planta; método para tratamento de infecção fúngica em uma planta; produto de tratamento de edifício antifúngico; método para tratamento de um edifício; e composto para uso
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
BR112015015864A2 (pt) composição farmacêutica, método de preparação de uma composição farmacêutica, método de tratamento de um indivíduo com uma condição de dor severa, e, uso de uma composição farmacêutica
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
WO2013192517A3 (en) Compounds for treating infectious diseases
BR112016005317A2 (pt) derivados de quinazolina e seu uso como inibidores de dna metiltransferase
WO2016100949A3 (en) Method and compositions for dissolving or solubilizing therapeutic agents
BR112015032534A2 (pt) usos de composto ou de sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, composições farmacêuticas e métodos para prevenir e/ou tratar encefalopatia traumática crônica ou condição relacionada em indivíduo e para tratar indivíduo com lesão de concussão
GR1008234B (el) Παρεντερικο σκευασμα ενος αντιμυκητιασικου παραγοντα τριαζολης και μεθοδος για την παρασκευη αυτου
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
BR112018070064A2 (pt) composições farmacêuticas estáveis para administração tópica e uso das mesmas
WO2017152130A8 (en) Pharmaceutical compositions
BR112018076229A2 (pt) formulação tópica e método de tratamento da pele seca pruriginosa causada por ureia de um indivíduo
BR112013004714A2 (pt) "combinações de inibidores de hdac com fármacos de trombocitopenia e seus usos"

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/11/2012, OBSERVADAS AS CONDICOES LEGAIS.